The lead protein, tTF-NGR (Histag-tTF1-218-GNGRAHA), has recently entered a clinical phase I dose-escalation study in patients with advanced solid tumors or lymphomas beyond standard therapies (NCT02902237). Here, TTF1 is linked to lymphoma.